Bristol-Myers Squibb Co

Explore how Bristol‑Myers Squibb’s FDA approval of Breyanzi for MZL is sparking a surge in shareholder value, analyst upgrades, and a promising oncology pipeline.

Explore Bristol‑Myers Squibb’s 2025 Q3 surge, new Sotyktu safety data, and bold Metsera bid—how this biopharma giant balances growth, value, and dividend returns.

Explore how Bristol‑Myers Squibb’s Q3 earnings and new Sotyktu data reveal a resilient growth engine amid patent pressure and strategic biotech moves.

Bristol-Myers Squibb’s (BMY) recent developments, including positive clinical trial results and analyst endorsements, reinforce its position as a compelling deep-value investment opportunity in the biopharmaceutical sector.

Bristol-Myers Squibb Co. reported a decrease in second-quarter profit, but exceeded market expectations, with adjusted results showing a 4.1% increase in revenue and a positive trajectory for the company.

Bristol-Myers Squibb Co. has entered a strategic partnership with BioNTech to co-develop and co-commercialize BNT327, a promising bispecific antibody candidate for treating multiple solid tumor types.

Bristol-Myers Squibb Co is a standout in the pharmaceutical industry, driven by its robust pipeline, strategic initiatives, and focus on innovative therapies, positioning it as a compelling investment opportunity amidst the domestic manufacturing boom.

Bristol-Myers Squibb Co is a key player in the pharma sector, with strong performance and growth potential driven by emerging market opportunities, favorable market conditions, and strategic positioning.